Open‐label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome)

• Published in: BJU international 2016-05, Vol.117 (5), p.809-813
• Main Authors: Panicker, Jalesh N., Seth, Jai H., Khan, Shahid, Gonzales, Gwen, Haslam, Collette, Kessler, Thomas M., Fowler, Clare J.
• Format: Article
• Language: English
• Subjects: Acetylcholine Release Inhibitors - administration & dosage; Acetylcholine Release Inhibitors - adverse effects; Adult; Aged; Ambulatory Care; Botulinum Toxins, Type A - administration & dosage; Botulinum Toxins, Type A - adverse effects; Excretory system; Female; Fowler's syndrome; Humans; Injections; Middle Aged; onabotulinumtoxinA; Pilot Projects; Prospective Studies; Retention; Treatment Outcome; Urethra - physiopathology; urethral sphincter; Urinary incontinence; Urinary Retention - drug therapy; Urinary Retention - etiology; Urinary Retention - physiopathology; Urination; Urogenital system
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.13342

Objectives To assess the efficacy (defined as improvements in maximum urinary flow rate [Qmax] of ≥50%, post‐void residual urine volume [PVR] and scores on the International Prostate Symptom Score [IPSS] questionnaire) and safety of urethral sphincter injections of onabotulinumtoxinA in women with a primary disorder of urethral sphincter relaxation, characterised by an elevated urethral pressure profile (UPP) and specific findings at urethral sphincter electromyography (EMG), i.e. Fowler's syndrome. Patients and Methods In this open‐label pilot Institutional Review Board‐approved study, 10 women with a primary disorder of urethral sphincter relaxation (elevated UPP, sphincter volume, and abnormal EMG) presenting with obstructed voiding (five) or in complete urinary retention (five) were recruited from a single tertiary referral centre. Baseline symptoms were assessed using the IPSS, and Qmax and PVR were measured. After 2% lidocaine injection, 100 U of onabotulinumtoxinA was injected into the striated urethral sphincter, divided on either side, under EMG guidance. Patients were reviewed at 1, 4 and 10 weeks after injection, and assessed using the IPSS, Qmax and PVR measurements. The UPP was repeated at week 4. Results The mean (range) patient age was 40 (25–65) years, and the mean symptom scores on the IPSS improved from 25.6 to 14.1, and the mean ‘bother’ score reduced from 6.1 to 3.5 at week 10. As compared with a baseline mean Qmax of 8.12 mL/s in the women who could void, the Qmax improved to 15.8 mL/s at week 10. Four of the five women in complete retention could void spontaneously, with a mean Qmax of 14.3 mL/s at week 10. The mean PVR decreased from 260 to 89 mL and the mean static UPP improved from 113 cmH2O at baseline to 90 cmH2O. No serious side‐effects were reported. Three women with a history of recurrent urinary tract infections developed a urinary tract infection. There were no reports of stress urinary incontinence. Seven of the 10 women opted to return for repeat injections. Conclusions This pilot study shows an improvement in patient‐reported lower urinary tract symptoms, and the objective parameters of Qmax, PVR and UPP, at 10 weeks after urethral sphincter injections of onabotulinumtoxinA. No serious side‐effects were reported. This treatment could represent a safe outpatient treatment for young women in retention due to a primary disorder of urethral sphincter relaxation. However, a larger study is required to confirm the findings of t